{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T05:15:16Z","timestamp":1700198116333},"reference-count":44,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2005,5,24]],"date-time":"2005-05-24T00:00:00Z","timestamp":1116892800000},"content-version":"vor","delay-in-days":540,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Academy of Nurse Practitioners"],"published-print":{"date-parts":[[2003,12]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To review and discuss the clinical evaluation and therapeutic options for a postmenopausal woman with osteoporosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Data Sources<\/jats:title><jats:p>Review of scientific literature, practice guidelines, and a case study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>To prevent and treat postmenopausal osteoporosis, women should be encouraged to per\u2010form weight\u2010bearing exercise, to not smoke, and to optimize calcium and vitamin D intake through diet and supplements. Drug regimens are effective and well tolerated in post\u2010menopausal women with osteoporosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Implications for Practice<\/jats:title><jats:p>Drugs currently approved by the U.S. Food and Drug Administration for the treatment of postmenopausal osteoporosis include the bisphosphonates risedronate and alendronate; the selective estrogen receptor modulator, raloxifene; and intranasal calcitonin\u2010salmon spray. Bisphosphonates have demonstrated the most impressive fracture risk reduction in prospective clinical trials of women with post\u2010menopausal osteoporosis. Risedronate has consistently demonstrated significant reductions in vertebral fracture risk at 1 year and in vertebral and nonvertebral fracture risk at 3 years. Alendronate has demonstrated significant reductions in vertebral and nonvertebral fracture risk after 3 years.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1745-7599.2003.tb00345.x","type":"journal-article","created":{"date-parts":[[2005,5,24]],"date-time":"2005-05-24T14:09:54Z","timestamp":1116943794000},"page":"539-540","source":"Crossref","is-referenced-by-count":3,"title":["An Approach to Postmenopausal Osteoporosis Treatment: A Case Study Review"],"prefix":"10.1111","volume":"15","author":[{"given":"Cathy","family":"Kessenich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,5,24]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07088-2"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.11.6953"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-002-2011-8"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001980070075"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00490-3"},{"key":"e_1_2_1_7_1","first-page":"S197","article-title":"Risedronate rapidly and consistently reduces risk of vertebral fracture in patients with varying degree of osteoporotic severity [Abstract]","volume":"43","author":"Cohen S.","year":"2000","journal-title":"Arthritis and Rheumatism"},{"key":"e_1_2_1_8_1","first-page":"704","article-title":"A new probable increasing cause of esophageal ulceration: Alendronate","volume":"92","author":"Colina R. E.","year":"1997","journal-title":"American Journal of Gastroenterology"},{"key":"e_1_2_1_9_1","unstructured":"Cummings S. Black D. &Vogt T.(1996).Changes in BMD substantially underestimate the antifracture effects of alendronate and other antiresorptive drugs. Paper presented at the American Society of Bone and Mineral Research[JBK5] Seattle WA."},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.24.2077"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199503233321202"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610033351403"},{"key":"e_1_2_1_13_1","volume-title":"Evista: Full prescribing information","author":"Eli Lilly and Company","year":"2001"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.7.637"},{"issue":"10","key":"e_1_2_1_15_1","first-page":"1377","article-title":"Clinic visits and hospital admissions for care of acid\u2010related upper gastrointestinal disorders in women using alendronate for osteoporosis","volume":"4","author":"Ettinger B.","year":"1998","journal-title":"American Journal of Managed Care"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.1.107"},{"key":"e_1_2_1_17_1","unstructured":"Harrington J. Eastell R. &Barton I.(2002 June).Risedronate significantly reduces nonvertebral fractures as soon as 6 months in postmenopausal osteoporosis [Abstract]. Presented at the 83rd annual meeting of the Endocrine Society. San Francisco."},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.14.1344"},{"key":"e_1_2_1_19_1","first-page":"293","article-title":"American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis","volume":"7","author":"Hodgson S. F","year":"2001","journal-title":"Endocrine Practice"},{"issue":"1","key":"e_1_2_1_20_1","first-page":"S428","article-title":"Similargastrointestinal side effects and endoscopic findings between risedronate\u2010 and placebo\u2010treated patients [Abstract]","volume":"15","author":"Hosking D.","year":"2000","journal-title":"Journal of Bone and Mineral Research"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)90023-1"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.16517"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)89446-6"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511303332201"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610033351416"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0029-7844(95)00430-0"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200102013440503"},{"key":"e_1_2_1_28_1","volume-title":"Fosamax: Full prescribing information","author":"Merck and Company","year":"2000"},{"key":"e_1_2_1_29_1","volume-title":"Physician's guide to prevention and treatment of osteoporosis","author":"National Osteoporosis Foundation","year":"1999"},{"key":"e_1_2_1_30_1","unstructured":"National Osteoporosis Foundation disease statistics. Retrieved May 28 2002 fromhttp:\/\/wwwnoforg\/osteoporosis\/statshtm."},{"key":"e_1_2_1_31_1","volume-title":"Miacalcin: Full prescribing information","author":"Novartis Pharmaceuticals Corporation","year":"2001"},{"key":"e_1_2_1_32_1","unstructured":"Pols H. Eastell R. Delmas P. Adachi K. Ensrud K. Harper S. et al. (2001).Early onset and sustained efficacy of raloxifene on incident vertebral fractures in postmenopausal women with osteoporosis: 4\u2010year results from the MORE Trial [Abstract OR64].Bone 28(Suppl.) S85."},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00004171"},{"key":"e_1_2_1_34_1","volume-title":"Actonel: Full prescribing information","author":"Procter and Gamble Pharmaceuticals","year":"2002"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1997.12.1.24"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001980050010"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5107(98)70256-1"},{"issue":"12","key":"e_1_2_1_38_1","first-page":"2648","article-title":"Improper alendronate administration and a case of pill esophagitis","volume":"91","author":"Rimmer D. E.","year":"1996","journal-title":"American Journal of Gastroenterology"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.206.2.9457190"},{"key":"e_1_2_1_40_1","first-page":"1","article-title":"Therapeutic equivalence of alendronate 70 mg once\u2010weekly and alendronate 10 mg daily in the treatment of osteoporosis: Alendronate Once\u2010Weekly Study Group","volume":"12","author":"Schnitzer T.","year":"2000","journal-title":"Aging"},{"key":"e_1_2_1_41_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1005544"},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5107(01)80511-3"},{"issue":"1","key":"e_1_2_1_43_1","first-page":"S407","article-title":"Risedronate reduces the risk of clinical vertebral fractures in just 6 months","volume":"16","author":"Watts N.","year":"2001","journal-title":"Journal of Bone and Mineral Research"},{"issue":"2","key":"e_1_2_1_44_1","first-page":"S203","article-title":"BMD change explains only a fraction of the observed fracture risk reduction in risedronate\u2010treated patients","volume":"11","author":"Watts N.","year":"2000","journal-title":"Osteoporosis International"},{"key":"e_1_2_1_45_1","first-page":"1","volume-title":"World Health Organization Technical Report Series","author":"World Health Organization","year":"1994"}],"container-title":["Journal of the American Academy of Nurse Practitioners"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1745-7599.2003.tb00345.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1745-7599.2003.tb00345.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T02:30:55Z","timestamp":1700188255000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1745-7599.2003.tb00345.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["10.1111\/j.1745-7599.2003.tb00345.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1745-7599.2003.tb00345.x","archive":["Portico"],"relation":{},"ISSN":["1041-2972","1745-7599"],"issn-type":[{"value":"1041-2972","type":"print"},{"value":"1745-7599","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}